May 15, 2026 This Week in Cardiology
This Week in Cardiology
Medscape Podcasts
4.9 • 963 Ratings
🗓️ 15 May 2026
⏱️ 31 minutes
🧾️ Download transcript
Summary
Another positive digoxin trial, another classic coronary physiology study from Imperial College London (ORBITA-FIRE), news in hypertrophic cardiomyopathy, and TAVR done in the wrong patients are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Digoxin in Rheumatic Heart Disease
- Dig-RHD Trial https://jamanetwork.com/journals/jama/fullarticle/2848973
- Safety and Efficacy of Digoxin: Meta-Analysis https://www.bmj.com/content/351/bmj.h4451.long
- DIGIT-HF Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2415471
- DIG Trial https://www.nejm.org/doi/full/10.1056/NEJM199702203360801
- RADIANCE Trial https://www.nejm.org/doi/full/10.1056/NEJM199307013290101
II The Physiologic Threshold for Angina
- ORBITA-FIRE Trial https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.125.078738
III Prediction in Hypertrophic Cardiomyopathy
- Predictors of Long-Term Outcomes in HCM https://jamanetwork.com/journals/jama/fullarticle/2848800#250998713
IV TAVR Trends in Young Patients
- Temporal Trends in AVR for Aortic Stenosis in Patients < 65 https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.126.016826
- Wall Street Journal article https://www.wsj.com/health/healthcare/heart-valve-tavr-surgery-aorta-1e0eda70
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Transcript
Click on a timestamp to play from that location
| 0:00.0 | You're listening to This Week in Cardiology from the heart.org, Medscape Cardiology. |
| 0:05.7 | This podcast is intended for health care professionals only. |
| 0:08.8 | Any views expressed are the presenters' own and do not necessarily reflect the views of WebMD or Medscape. |
| 0:14.6 | Hi, everyone. |
| 0:16.0 | This is John Mandrola from the Heart.org Medscape Cardiology, and this is this week in cardiology for May 15th |
| 0:24.1 | 2026. This week another positive dejoxin trial and another classic coronary physiology study from |
| 0:32.5 | the Imperial College London group study called Orbita Fire, big news in hypertrophic cardiomyopathy, |
| 0:40.3 | and Taver done in the wrong patients. |
| 0:43.3 | The first topic is that JAMA has published the placebo-controlled randomized DIG-R-D trial. |
| 0:50.3 | RHD stands for rheumatic heart disease. |
| 0:53.3 | More than 1,700 patients with symptomatic rheumatic heart disease were randomized to dejoxin or placebo, |
| 0:59.0 | and the primary outcome was a composite of all-caused death or new onset worsening heart fire. |
| 1:04.0 | The trial was carried out in 12 tertiary care hospitals in India, |
| 1:08.0 | and as a matter of background, rheumatic heart disease is an important |
| 1:11.6 | cause of morbidity and mortality among young people in low and middle income countries. |
| 1:17.3 | It affects more than 40 million people worldwide and causes 1.2 million cases of heart failure |
| 1:22.6 | and nearly 320,000 deaths annually. In low and middle income countries, |
| 1:28.3 | rheumatic heart disease accounts for 25% of heart failure |
| 1:31.3 | with preserved dejection fraction, |
| 1:33.3 | and most deaths in rheumatic heart disease are heart failure related. |
| 1:37.3 | Now, patients in the Didge Arm could receive either 0.25 or 0.125 |
| 1:41.3 | based on a doctor's choice. These patients enrolled in the trial were 46 years old, |
... |
Transcript will be available on the free plan in 8 days. Upgrade to see the full transcript now.
Disclaimer: The podcast and artwork embedded on this page are from Medscape Podcasts, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Medscape Podcasts and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.